TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Analysis of Effects and Side Effects in Patients Undergoing Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing radiotherapy at the Kantonsspital Graubuenden~Exclusion Criteria:~* No radiotherapy at Kantonsspital Graubuenden~* Age: \< 20 years, \> 105 years

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 105 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Functional Outcome Study of the Knee

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is a male or non-pregnant female age 18 years or older at time of study~* Patient is a candidate for a total knee arthroplasty~* Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.~Exclusion Criteria:~* Patients younger than 18 years of age~* Patients with a primary diagnosis other than osteoarthritis of the knee as determined by an orthopaedic surgeon~* Patients who have had any previous lower extremity procedure~* Patients with a BMI greater than or equal to 40~* Patients with an active infection within the affected knee joint Patients with a neuromuscular or neurosensory deficiency that may limit the ability of the patient to evaluate the safety and efficacy of the device~* Patient is diagnosed with systemic disease or metabolic disorder leading to progressive bone deterioration (e.g. Lupus Erythematosus, Paget's Disease)~* Patient is immunologically suppressed or receiving chronic steroids in excess of normal physiological requirements (e.g. greater than 30 days)~* Patient has a known sensitivity to device materials~* Non-English speaking patients~* Patient is a prisoner

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total Knee Arthroplasty patients (Type: None): TKA patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative and Postoperative Incentive Spirometry in Patients Undergoing Major Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo major abdominal surgery with expected postoperative length of stay of 48 hours or more.~* Access to a smartphone.~* At least 18 years of age.~* Ability to understand and willingness to sign an IRB approved written informed consent document.~Exclusion Criteria:~* Younger than 18 years of age~* No access to a smartphone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-Surgery: No Incentive Spirometry (IS) (Type: NO_INTERVENTION): -Will not receive a incentive spirometer prior to surgery
- Pre-Surgery: Standard Incentive Spirometry (IS) (Type: EXPERIMENTAL): * Will receive a conventional spirometer prior to surgery~* Will be asked to perform spirometry 30 times per day.
- Pre-Surgery: Digital Incentive Spirometry (IS) + Text Message (Type: EXPERIMENTAL): * Will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~* Will be asked to perform spirometry 10 times per hour, every hour while awake, every day for at least 7 days prior to surgery. Absence of spirometry for 24 hours will trigger a text message reminder to encourage compliance with IS.
- Post-Surgery: Standard Incentive Spirometry (IS) (Type: ACTIVE_COMPARATOR): * After surgery, the participants will receive a conventional spirometer.~* Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~* The conventional spirometer will be equipped with an accelerometer that will allow the research team to determine whether the spirometer moves throughout the patients' postoperative stay (as a proxy for IS use)
- Post-Surgery: Digital Incentive Spirometry (IS) + Text Message (Type: EXPERIMENTAL): * After surgery, the participants will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~* Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~* Will receive text reminders to perform spirometry if they do not perform spirometry in a 24-hour period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Newly diagnosed intermittent claudication~* Ankle Brachial Index \< 0.8 at rest or \> 0.15 decrease after exercise~* Able to perform standardised treadmill walking test for 2 min~* Written informed consent~Exclusion Criteria:~* Unable to fill out a questionnaire (cognitive impairment or insufficient knowledge of the Dutch language)~* Heart failure or unstable cardiac status (angina pectoris class III or IV or recent myocardial infarction \< 3 months)~* Any illness with rapid evolution or a life expectancy \< 3 months~* Recent cerebrovascular accident (\< 3 months)~* Current use of fish oil supplements or \> 2 times a week dietary fish~* Pregnancy~* Fish, soybean or peanut allergy~* Contra indications for the use of omega-3 fatty acids~* Use of oral anticoagulants (coumarin derivatives)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supervised Exercise Therapy (Type: ACTIVE_COMPARATOR): Standard treatment: Supervised Exercise Therapy during 12 weeks
- Controlled group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is undergoing a routine (i.e., expected to be uncomplicated) total primary or secondary hip replacement surgery performed under a standardized regimen of spinal anesthesia, and is expected to experience moderate to severe post-surgical pain in the absence of post-operative analgesia~Exclusion Criteria:~* The patient is undergoing a revision to a previous hip replacement procedure, hip replacement procedure further to a road traffic accident with multiple injuries, or a procedure expected to last longer than 4 hours~* The patient has a history of uncontrolled chronic disease or a concurrent clinically significant illness or medical condition, which in the Investigator's opinion, would contraindicate study participation or confound interpretation of the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo as an adjunct to standard of care
- Pregabalin (Type: ACTIVE_COMPARATOR): Pregabalin as an adjunct to standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Donepezil on Sedation and Other Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with drowsiness/sedation caused by opiate for \> 3 days and its intensity more or equal to 3/10 (0 to 10 scale; 0 = no sedation, 10=worst possible sedation).~2. Patient receiving a regular dose of a strong opioid for the treatment of cancer pain, and no dose changes or dose change within 50% for at least 48 hours.Regular administration, defined as short acting opioids oral or parenteral every 4 hours around clock, slow release oral opioids every 12 hs or 24 hs, or transdermal opioids every 72 hours. Strong opioids include morphine, hydromorphone, methadone, fentanyl, and oxycodone.~3. Patient with relatively intact cognition defined by the Mini Mental State Examination according to age and educational level. A score of 24 or above is usually considered normal.~4. Patient willing to engage in follow up visit with a nurse by phone on day 2-7 (each day), 11 and 15 of the study and to return for follow up visit on day 8 of treatment. If patient is unable to come to clinic, assessment will be performed through telephone.~5. Sexually active females at risk of being pregnant with a negative urine pregnancy test~6. Written consent form signed.~7. Patients are 18 years or older~8. Concurrent radiation treatment (defined as 10 or less fractions for a palliative indication) is allowed~9. Concurrent chemotherapy is allowed, if the first two cycles have been well tolerated (defined as no grade 3 or 4 non-hematological toxicity)~Exclusion Criteria:~1. Major contraindication to donepezil i.e. hypersensitivity to donepezil or piperidine derivatives.~2. Patients in whom a major change in opiate dose, analgesia requirements, anesthetic procedures or general anesthetic is expected over the next seven days.~3. Treatment with anti-cholinergic agents (i.e., glycopyrrolate)~4. Patients taking Methylphenidate.~5. Patients with tube feeding (due to difficulty of accurate assessing some of the symptoms such as appetite and anorexia).~6. History of ongoing arrhythmia causing a rhythm other than a sinus rhythm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: ACTIVE_COMPARATOR): Oral Donepezil 5 mg daily x 7 days
- daily x 7 days (Type: PLACEBO_COMPARATOR): Placebo tablet daily x 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Propofol vs Propofol + Benzo/Opiates in High Risk Group

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide informed consent~* Age greater than or equal to 18 years~* Presence of at least 1 of the following criteria:~  1. ASA class 3 or higher~ 2. BMI of 30 or greater~ 3. At risk for OSA (score of 3 or greater on the STOP-BANG screening tool)~Exclusion Criteria:~* drug allergy to Propofol, Benzodiazepines, or Opioids~* patients who received Benzodiazepines or Opioids within 24 hours of the procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol+Benzo/Opioids (Type: ACTIVE_COMPARATOR): If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:~1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg
- Propofol Alone (Type: ACTIVE_COMPARATOR): The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:~* Induction Dose: 2-2.5 mg/kg~* Maintenance Dose: 0.1-0.2 mg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Initiated dialysis in past 3 months~* Signed informed consent~* Attending University of Iowa dialysis unit for duration of the study~Exclusion Criteria:~* Age \>70~* Unable to provide consent~* Currently taking fish oil supplementation~* rhythm other than sinus~* implantable cardioverter-defibrillator~* pacemaker~* myocardial infarction,revascularization or unstable angina in past 3 months~* other hospitalization in past 3 months~* symptomatic heart failure~* known left ventricular ejection fraction \< 30%~* history of a significant bleeding disorder~* severe bleeding episode requiring hospitalization in past 3 months (GI bleed or hemorrhagic stroke)~* unexplained HgB drop \> 2 gm/dl in past 3 months~* chronic warfarin or anti-coagulation therapy (such as Lovenox)~* pregnant or nursing mothers~* allergic to fish, fish oil or fish products~* Participation in other trials of investigational products~* other characteristics as determined by the investigator that would make sudy participation inappropriate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 4 capsules inert oil Placebo each day for 16 weeks
- Omega-3 Fatty Acid Ethyl Esters (Type: ACTIVE_COMPARATOR): 4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MitraClip System in Australia and New Zealand

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* MR ≥ 3+ .~* Transseptal catheterization and femoral vein access feasible.~* Placement of the MitraClip device on mitral leaflets feasible.~* Mitral valve orifice area ≥ 4.0 cm2.~* Written informed consent obtained.~* The patient agrees to return for follow-up visits.~Exclusion Criteria:~* Need for emergency surgery, other cardiac surgery.~* Coronary artery disease (CAD), atrial fibrillation (AF), other valve disease.~* Prior mitral valve repair surgery, mechanical prosthetic valve, or ventricular assist device (VAD).~* Active endocarditis or rheumatic heart disease; leaflets degenerated from endocarditis or rheumatic disease.~* Transesophageal echocardiography (TEE) contraindicated.~* Known hypersensitivity or contraindication to trial or procedure medications which cannot be managed medically.~* Currently participating in investigational drug trial or another device trial that has not yet completed the primary endpoint or that interferes with the MitraClip System ANZ Clinical Trial.~* Pregnant or planning pregnancy within next 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MitraClip Implant (Type: None): Eligible patients undergoing a MitraClip procedure in Australia and New Zealand

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Survey of Women's Choice of Delivery Before Consulting With Her Obstetrician

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant Women~* 18 years old or older~* Prior pregnancy with cesarean delivery~* No prior obstetric physician care during current pregnancy~Exclusion Criteria:~* More than one prior cesarean~* Women who cannot read English

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Women with a prior cesarean section (Type: None): Survey of women who had a cesarean section with their last pregnancy and no other prior cesarean section deliveries

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Daylight as Adjunctive Treatment in Patients With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfilling criteria for an ICD-10 diagnosis of unipolar depression (F. 32.0, F.32.1, F.32.2, F32.3, F. 32.8. F.33.0, F.33.1, F.33.2, F. 33.3)~* Hamilton Depression Score (HAM-D17) ≥ 12~* In treatment with the same antidepressant medication 14 days prior to inclusion~* The participant must have access to a smart phone~Exclusion Criteria:~* Actual treatment with Electro Convulsive Therapy (ECT)~* Seasonal Affective Disorder (SAD)~* Known sleep disturbances (sleep-apnoea, narcolepsy, or restless legs syndrome)~* On lithium, agomelatine, melatonin and/or mirtazapine~* Known eye disorders~* Current alcohol- or drug abuse~* Current user of Light therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (intervention group) (Type: EXPERIMENTAL): Regular exposure to morning daylight
- Group 2 (control group) (Type: NO_INTERVENTION): Treatment as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Biochemical Makers for Outcome After Pediatric out-of Hospital Cardiac Arrest

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children between 2 weeks -18 years of age~* Child who suffered an out of hospital CA: defined as Cessation of cardiac mechanical activity as confirmed by the absence of signs of circulation. Includes the following rhythms: pulseless electrical activity (PEA), asystole, ventricular tachycardia, and ventricular fibrillation with the need od chest compressions.~* Children admitted to the Department of pediatric anesthesia and intensive care~* Children have vascular access for blood draws as part of their standard of care~* Children have a pre-CA Pediatric Cerebral Performance Category (PCPC) score of 1- 3.~Exclusion Criteria:~* Patients with brain injury of other etiologies. (trauma, abscess, tumor, bacterial meningitis)~* Children with do not resuscitate (DNR) status~* Pregnancy~* Metabolic or other disease affecting the brain (eg. refractory epilepsy)

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Pediatric patients after out-of hospital cardiac arrest (Type: None): Pediatric patients after out-of hospital cardiac arrest admitted to Department of pediatric anesthesia and intensive care University hospital in Brno in selected study period with blood sample analysis for neurologic outcome prognostication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Daytime Impact Sleep Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 2 night time voids per night~* Habitual sleep of 6-9.5 hours per night~* Experiencing symptoms of Nocturia greater than 6 months~Exclusion Criteria:~* Greater than 10 night time voids~* History of sleep apnoea and PLMS (Periodic Limb Movements of Sleep)~* Other sleep disorders~* Signs or symptoms of: Bladder outlet obstruction, severe lower urinary tract symptoms (LUTS), interstitial cystitis, moderate to severe overactive bladder (OAB), moderate to severe as judged by the investigator stress urinary incontinence~* Urological malignancies~* Neurogenic detrusor over activity (e.g. Parkinson, spinal cord damage, etc.)~* Central or nephrogenic diabetes insipidus~* Habitual or psychogenic polydipsia (fluid intake resulting in a urine production exceeding 40ml/Kg/24hrs)~* Syndrome of inappropriate antidiuretic hormone (SIADH)~* Cardiac failure evidence based on physical examination, cardiac medical history and electrocardiogram (ECG) output~* Uncontrolled hypertension~* Uncontrolled diabetes mellitus~* Hyponatraemia with sodium \<135 mmol/L~* Renal insufficiency~* Known or suspected clinically significant hepatic and/or biliary diseases

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental A (Type: EXPERIMENTAL): None
- Experimental B (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy